OptiNose (NASDAQ: OPTN) is a specialty pharmaceutical company. OptiNose is dedicated to improving the quality of life for patients cared for directly by, or in consultation with ENT or allergy specialists by creating and bringing to market innovative products. OptiNose’s first two products rely on patented Exhalation Delivery Systems (EDS) capable of deep intranasal deposition of medication. OptiNose’s second product, XHANCE (fluticasone propionate) nasal spray, is approved for the treatment of nasal polyps.
Headquarters: Yardley, PA